ZEN 3694 - Zenith Epigenetics

Drug Profile

ZEN 3694 - Zenith Epigenetics

Alternative Names: ZEN-003694; ZEN-3694

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zenith Epigenetics Corp
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Breast cancer; Haematological malignancies; Lung cancer

Most Recent Events

  • 05 Dec 2017 Pharmacodynamics data from a preclinical trial in breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 01 Oct 2017 Zenith Epigenetics Corp completes a phase I trial for Prostate cancer (Metastatic disease, Hormone refractory) in USA (PO) (NCT02705469)
  • 19 Jun 2017 Preclinical trials in Breast cancer in Canada (PO) before June 2017 (Zenith Epigenetics pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top